Analgesia can be produced by opioid agonists microinjected intraventricularly (supra-spinal) or intrathecally (spinal). Thus both spinal and supraspinal brain sites contain opioid sensitive structures mediating analgesia. Recent studies indicate that morphine and other opioids produce analgesia in part through an indirect mechanism involving the activation of an intrinsic descending pain inhibitory system. My preliminary studies in rats showed that intrathecal naloxone antagonized completely the analgesia produced by intraventricular Beta-endorphin but not that by morphine. Intraventricularly, Beta-endorphin, but nor morphine releases immunoreactive (i.r.) met-enkephalin from the spinal cord while intraventricular morphine but not Beta-endorphin releases i.r. dynorphin 1-8. This evidence supports the hypothesis that Beta-endorphin and morphine elicit the analgesic action via the activation of different neuronal mechanisms. A model working hypothesis for the action of Beta-endorphin and morphine is proposed. The hypothesis is that the descending inhibitory systems can be divided into two systems: an epsilon-opioid receptor mediated descending system and a mu-opioid receptor mediated descending system. The first system is activated by supraspinal Beta-endorphin and is mediated by a spinal enkephalinergic system. The second system is activated by supraspinal morphine and other mu-receptor agonists and is mediated by a spinal dynorphinergic system. The proposed studies are aimed to obtain more evidence to verify this hypothesis by studying the spinal release of endorphins by intraventricular Beta-endorphin, morphine and other opiates in male albino rabbits, cats and male Sprague-Dawley rats. The release of endorphins (met-enkephalin, dynorphin 1-8, and other endorphins) and serotonin and norepinephrine from the spinal cord by intraventricular Beta-endorphin, morphine and other opioid agonists will be studied. A spinal intrathecal superfusion technique will be used to study the spinal release of endophins and biogenic amines. The endorphins in the superfusate will be assayed by radioimmunoassay and also analyzed by HPLC. The serotonin and norepinephrine will be separated by HPLC and quantified with electrochemical detection. Chronic exposure of opioids on the development of the tolerance on the spinal release of i.r. met-endephalin and dynorphin 1-8 by Beta-endorpin and morphine respectively will also be studied. The proposed studies will provide evidence of a physiological role as neurotransmitter for spinal enkephalin and dynorphin and their association with descending analgesic systems.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA003811-03
Application #
3208502
Study Section
(DABA)
Project Start
1985-01-01
Project End
1988-06-30
Budget Start
1987-01-01
Budget End
1988-06-30
Support Year
3
Fiscal Year
1987
Total Cost
Indirect Cost
Name
Medical College of Wisconsin
Department
Type
Schools of Medicine
DUNS #
073134603
City
Milwaukee
State
WI
Country
United States
Zip Code
53226
Terashvili, Maia; Wu, Hsiang-En; Leitermann, Randy J et al. (2005) Differential mechanisms of antianalgesia induced by endomorphin-1 and endomorphin-2 in the ventral periaqueductal gray of the rat. J Pharmacol Exp Ther 312:1257-65
Wu, Hsiang-En; Thompson, Jonathan; Sun, Han-Sen et al. (2004) Nonopioidergic mechanism mediating morphine-induced antianalgesia in the mouse spinal cord. J Pharmacol Exp Ther 310:240-6
Mizoguchi, Hirokazu; Leitermann, Randy J; Narita, Minoru et al. (2004) Region-dependent G-protein activation by kappa-opioid receptor agonists in the mouse brain. Neurosci Lett 356:145-7
Ohsawa, Masahiro; Mizoguchi, Hirokazu; Narita, Minoru et al. (2003) Involvement of beta-arrestin-2 in modulation of the spinal antinociception induced by mu-opioid receptor agonists in the mouse. Neurosci Lett 346:13-6
Mizoguchi, Hirokazu; Wu, Hsiang-En; Narita, Minoru et al. (2003) Lack of mu-opioid receptor-mediated G-protein activation in the spinal cord of mice lacking Exon 1 or Exons 2 and 3 of the MOR-1 gene. J Pharmacol Sci 93:423-9
Mizoguchi, Hirokazu; Hung, Kuei-chun; Leitermann, Randy et al. (2003) Blockade of mu-opioid receptor-mediated G-protein activation and antinociception by TRK-820 in mice. Eur J Pharmacol 461:35-9
Wu, Hsiang-En; Sun, Han-Sen; Darpolar, Moses et al. (2003) Dynorphinergic mechanism mediating endomorphin-2-induced antianalgesia in the mouse spinal cord. J Pharmacol Exp Ther 307:1135-41
Wu, Hsiang-en; Sun, Han-Sen; Darpolar, Moses et al. (2003) Antinociceptive properties of oxymorphazole in the mouse. Eur J Pharmacol 473:143-8
Mizoguchi, Hirokazu; Spaulding, Amanda; Leitermann, Randy et al. (2003) Buprenorphine blocks epsilon- and micro-opioid receptor-mediated antinociception in the mouse. J Pharmacol Exp Ther 306:394-400
Hung, Kuei-chun; Wu, Hsiang-en; Mizoguchi, Hirokazu et al. (2003) Intrathecal treatment with 6-hydroxydopamine or 5,7-dihydroxytryptamine blocks the antinociception induced by endomorphin-1 and endomorphin-2 given intracerebroventricularly in the mouse. J Pharmacol Sci 93:299-306

Showing the most recent 10 out of 107 publications